More than 130 million people around the globe suffer from psoriasis vulgaris, a chronic condition characterized by skin inflammation, scales, and dry patches. However, its pathology is not fully clear. In a recent study, dermatology researchers from Japan have uncovered a complex cellular mechanism responsible for the onset of psoriasis and highlighted potential therapeutic targets for future treatment.
State crisis standards of care (CSC) guidelines in the U.S. allocate scarce health care resources among patients, and this study examined the implications of these guidelines for patients with cancer, including allocation methods, cancer-related categorical exclusions and deprioritizations, and provisions for blood products and palliative care.
Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 - 8, 2020.
Metabolites are small molecules found in our body's cells. They come from the food we eat, chemical processes happening within our bodies and microbes. A new analysis of recent studies has found that the levels of 10 metabolites detected in the blood are associated with a person's risk of stroke. The research is published in the December 2, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use of high-dose Octagam® 10% [Immune Globulin Intravenous (Human)] for the most severe COVID-19 patients. Octapharma's intravenous immunoglobulin (IVIg) portfolio also will be featured in a study design poster focused on primary infection prophylaxis in patients with chronic lymphocytic leukemia during ASH, to be held virtually December 5 - 8 due to the coronavirus pandemic.
Octapharma USA will present its most recent rare bleeding disorders research initiatives during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, a virtual medical congress to be held December 5 - 8.
Iron-deficiency anaemia is a major concern in low-income settings, especially for women. In a new study by the Swiss Tropical and Public Health Institute (Swiss TPH) and partners published yesterday in The Lancet Global Health, researchers found that iron infusion was feasible, safe and, in contrast to the standard iron-deficiency anaemia treatment of oral iron tablets, highly effective in Tanzania. This is the first study to provide evidence of the benefits and safety of iron infusion in a low-income setting.
Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies. The 'cell survival protein', called BCL-XL, was required in laboratory models to keep kidney cells alive and functioning during exposure to chemotherapy or radiotherapy. Kidney damage is a common side effect of these widely used cancer therapies, and the discovery has shed light on how this damage occurs at the molecular level.
Researchers at Emory and Case Western Reserve have re-engineered an oncolytic adenovirus. The resulting virus is not easily caught by parts of the innate immune system, making systemic delivery possible without arousing a massive inflammatory reaction.
Men who have the Western world's most common genetic disorder, haemochromatosis, are ten times more likely to develop liver cancer, according to a major new study.